BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 16540312)

  • 1. Inhibition of the mammalian target of rapamycin (mTOR) by rapamycin increases chemosensitivity of CaSki cells to paclitaxel.
    Faried LS; Faried A; Kanuma T; Nakazato T; Tamura T; Kuwano H; Minegishi T
    Eur J Cancer; 2006 May; 42(7):934-47. PubMed ID: 16540312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of mTOR signaling pathway contributes to survival of cervical cancer cells.
    Ji J; Zheng PS
    Gynecol Oncol; 2010 Apr; 117(1):103-8. PubMed ID: 20102778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines.
    Aissat N; Le Tourneau C; Ghoul A; Serova M; Bieche I; Lokiec F; Raymond E; Faivre S
    Cancer Chemother Pharmacol; 2008 Jul; 62(2):305-13. PubMed ID: 17912526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential sensitivity of paclitaxel-induced apoptosis in human esophageal squamous cell carcinoma cell lines.
    Faried A; Faried LS; Kimura H; Sohda M; Nakajima M; Miyazaki T; Kato H; Kanuma T; Kuwano H
    Cancer Chemother Pharmacol; 2006 Feb; 57(3):301-8. PubMed ID: 16028102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of an activated mammalian target of rapamycin in adenocarcinoma of the cervix: A potential biomarker and molecular target therapy.
    Faried LS; Faried A; Kanuma T; Aoki H; Sano T; Nakazato T; Tamura T; Kuwano H; Minegishi T
    Mol Carcinog; 2008 Jun; 47(6):446-57. PubMed ID: 18058806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapamycin induces apoptosis of JN-DSRCT-1 cells by increasing the Bax : Bcl-xL ratio through concurrent mechanisms dependent and independent of its mTOR inhibitory activity.
    Tirado OM; Mateo-Lozano S; Notario V
    Oncogene; 2005 May; 24(20):3348-57. PubMed ID: 15782132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer.
    Liu H; Zang C; Emde A; Planas-Silva MD; Rosche M; Kühnl A; Schulz CO; Elstner E; Possinger K; Eucker J
    Eur J Pharmacol; 2008 Sep; 591(1-3):43-51. PubMed ID: 18588872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells.
    Mondesire WH; Jian W; Zhang H; Ensor J; Hung MC; Mills GB; Meric-Bernstam F
    Clin Cancer Res; 2004 Oct; 10(20):7031-42. PubMed ID: 15501983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.
    Schwock J; Pham NA; Cao MP; Hedley DW
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):669-81. PubMed ID: 17579866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Involvement of both extrinsic and intrinsic apoptotic pathways in apoptosis induced by genistein in human cervical cancer cells.
    Kim SH; Kim SH; Lee SC; Song YS
    Ann N Y Acad Sci; 2009 Aug; 1171():196-201. PubMed ID: 19723056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The mTOR inhibitor enhances chemosensitivity of androgen-independent prostate cancer cell line].
    Xia JS; Chen XG; Zhuang QY; Liu JH; Ye ZQ
    Zhonghua Nan Ke Xue; 2009 Jul; 15(7):617-20. PubMed ID: 19694375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sensitivity to Fas-mediated apoptosis in high-risk HPV-positive human cervical cancer cells: relationship with Fas, caspase-8, and Bid.
    Hougardy BM; van der Zee AG; van den Heuvel FA; Timmer T; de Vries EG; de Jong S
    Gynecol Oncol; 2005 May; 97(2):353-64. PubMed ID: 15863130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AICAR inhibits proliferation and induced S-phase arrest, and promotes apoptosis in CaSki cells.
    Guan TJ; Qin FJ; Du JH; Geng L; Zhang YY; Li M
    Acta Pharmacol Sin; 2007 Dec; 28(12):1984-90. PubMed ID: 18031613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells.
    Hosoi H; Dilling MB; Shikata T; Liu LN; Shu L; Ashmun RA; Germain GS; Abraham RT; Houghton PJ
    Cancer Res; 1999 Feb; 59(4):886-94. PubMed ID: 10029080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The mTOR inhibitor RAD001 sensitizes tumor cells to the cytotoxic effect of carboplatin in breast cancer in vitro.
    Liu H; Zang C; Schefe JH; Schwarzlose-Schwarck S; Regierer AC; Elstner E; Schulz CO; Scholz C; Possinger K; Eucker J
    Anticancer Res; 2011 Sep; 31(9):2713-22. PubMed ID: 21868512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic effect of rapamycin and cisplatin in endometrial cancer cells.
    Bae-Jump VL; Zhou C; Boggess JF; Gehrig PA
    Cancer; 2009 Sep; 115(17):3887-96. PubMed ID: 19484784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 3,3'-diindolylmethane and paclitaxel act synergistically to promote apoptosis in HER2/Neu human breast cancer cells.
    McGuire KP; Ngoubilly N; Neavyn M; Lanza-Jacoby S
    J Surg Res; 2006 May; 132(2):208-13. PubMed ID: 16580691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro.
    Gorshtein A; Rubinfeld H; Kendler E; Theodoropoulou M; Cerovac V; Stalla GK; Cohen ZR; Hadani M; Shimon I
    Endocr Relat Cancer; 2009 Sep; 16(3):1017-27. PubMed ID: 19509067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Damaged microtubules can inactivate BCL-2 by means of the mTOR kinase.
    Calastretti A; Bevilacqua A; Ceriani C; Viganò S; Zancai P; Capaccioli S; Nicolin A
    Oncogene; 2001 Sep; 20(43):6172-80. PubMed ID: 11593425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced radiation damage of tumor vasculature by mTOR inhibitors.
    Shinohara ET; Cao C; Niermann K; Mu Y; Zeng F; Hallahan DE; Lu B
    Oncogene; 2005 Aug; 24(35):5414-22. PubMed ID: 15940265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.